CAR-DC therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new cell therapy called CAR-DC for people with advanced solid tumors that have certain markers on their cells. It aims to see if it is safe and works against cancers like lung, liver, stomach, or colorectal cancer that haven't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have an advanced solid tumor (cancer that has spread or is locally advanced) that tests positive for at least one of these markers: EphA2, Claudin18.2, TROP2, HER2, GCC, GPC-3, or CEA.
- Standard treatments have stopped working, or you cannot take them due to side effects or other reasons.
- You are able to get out of bed and take care of yourself (ECOG score 0-2).
- Your organs (bone marrow, kidneys, blood clotting) and oxygen levels are functioning well enough, based on blood and other tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new treatment using modified natural killer cells (CAR-NK) that target two specific proteins found on your cancer cells. It is for people with advanced colorectal cancer who have tried standard treatments without success.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.